Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen K Chia

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Cancer Treatment Reviews|February 28, 2012
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trialsJohn R Mackey, Robert S Kerbel, Karen A Gelmon, et al.
Cancer Research|August 4, 2004
Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progressionAruna Somasiri, Julie S Nielsen, Nikita Makretsov, et al.
Investigational New Drugs|January 8, 2020
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysisJean-Michel Lavoie, Teresa Mitchell, Sung-Eun Lee, et al.
Journal of the National Cancer Institute|May 14, 2009
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerMaggie C U Cheang, Stephen K Chia, David Voduc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survivalMaggie C U Cheang, Diana O Treaba, Caroline H Speers, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2020
<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT TrialsNicholas C Turner, Claire Swift, Lucy Kilburn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2012
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifenStephen K Chia, Vivien H Bramwell, Dongsheng Tu, et al.
Journal of the National Cancer Institute|May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancerEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Cancer Research Communications|December 5, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid TumorsTharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cancer Treatment Reviews|February 28, 2012
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trialsJohn R Mackey, Robert S Kerbel, Karen A Gelmon, et al.
Cancer Research|August 4, 2004
Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progressionAruna Somasiri, Julie S Nielsen, Nikita Makretsov, et al.
Investigational New Drugs|January 8, 2020
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysisJean-Michel Lavoie, Teresa Mitchell, Sung-Eun Lee, et al.
Journal of the National Cancer Institute|May 14, 2009
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerMaggie C U Cheang, Stephen K Chia, David Voduc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survivalMaggie C U Cheang, Diana O Treaba, Caroline H Speers, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2020
<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT TrialsNicholas C Turner, Claire Swift, Lucy Kilburn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2012
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifenStephen K Chia, Vivien H Bramwell, Dongsheng Tu, et al.
Journal of the National Cancer Institute|May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancerEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Cancer Research Communications|December 5, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid TumorsTharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, et al.
Pageof 4